Grail (NASDAQ:GRAL) Trading 5% Higher – Should You Buy?

Grail, Inc. (NASDAQ:GRAL) traded up 5% on Thursday . The stock traded as high as $21.60 and last traded at $21.48. 203,860 shares were traded during trading, a decline of 81% from the average session volume of 1,061,534 shares. The stock had previously closed at $20.46.

Analyst Ratings Changes

GRAL has been the subject of a number of analyst reports. Wolfe Research began coverage on Grail in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Morgan Stanley began coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price target for the company. Finally, Guggenheim initiated coverage on shares of Grail in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock.

Grail Price Performance

The stock’s fifty day simple moving average is $15.68.

Insider Activity

In other news, CEO Robert P. Ragusa sold 123,454 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Chun R. Ding acquired 7,629 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was acquired at an average cost of $13.52 per share, with a total value of $103,144.08. Following the completion of the purchase, the insider now owns 3,503,655 shares of the company’s stock, valued at $47,369,415.60. This trade represents a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 58,829 shares of company stock valued at $757,298.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.